NRx Pharmaceuticals Statistics Share Statistics NRx Pharmaceuticals has 19.5M
shares outstanding. The number of shares has increased by 81.44%
in one year.
Shares Outstanding 19.5M Shares Change (YoY) 81.44% Shares Change (QoQ) 15.3% Owned by Institutions (%) 13.78% Shares Floating 16.17M Failed to Deliver (FTD) Shares 480 FTD / Avg. Volume 0.18%
Short Selling Information The latest short interest is 799.53K, so 4.1% of the outstanding
shares have been sold short.
Short Interest 799.53K Short % of Shares Out 4.1% Short % of Float 4.51% Short Ratio (days to cover) 5.46
Valuation Ratios The PE ratio is -0.92 and the forward
PE ratio is 3.15.
NRx Pharmaceuticals's PEG ratio is
0.02.
PE Ratio -0.92 Forward PE 3.15 PS Ratio 0 Forward PS 0.4 PB Ratio -1 P/FCF Ratio -2.18 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for NRx Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.15,
with a Debt / Equity ratio of -0.28.
Current Ratio 0.15 Quick Ratio 0.15 Debt / Equity -0.28 Debt / EBITDA -0.36 Debt / FCF -0.62 Interest Coverage -80.44
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-12.56M Employee Count 2 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 13.66% in the
last 52 weeks. The beta is 1.6, so NRx Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.6 52-Week Price Change 13.66% 50-Day Moving Average 3.08 200-Day Moving Average 2.37 Relative Strength Index (RSI) 32.84 Average Volume (20 Days) 271,083
Income Statement
Revenue n/a Gross Profit n/a Operating Income -18.5M Net Income -25.13M EBITDA -18.5M EBIT -24.9M Earnings Per Share (EPS) -2.39
Full Income Statement Balance Sheet The company has 1.44M in cash and 6.58M in
debt, giving a net cash position of -5.13M.
Cash & Cash Equivalents 1.44M Total Debt 6.58M Net Cash -5.13M Retained Earnings -278.27M Total Assets 7.59M Working Capital -25.5M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -10.64M
and capital expenditures 0, giving a free cash flow of -10.64M.
Operating Cash Flow -10.64M Capital Expenditures n/a Free Cash Flow -10.64M FCF Per Share -1.01
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields NRXP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for NRXP is $31,
which is 1230.5% higher than the current price. The consensus rating is "Buy".
Price Target $31 Price Target Difference 1230.5% Analyst Consensus Buy Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 2, 2024. It was a
backward
split with a ratio of 1:10.
Last Split Date Apr 2, 2024 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -65.96 Piotroski F-Score 3
